Teresa Zimmers, professor of cell, developmental and cancer biology at the Oregon Health & Sciences University School of Medicine, at 12:55 p.m. Wednesday, Jan. 29, on Zoom.

Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with advanced cancer. A new study from Japan has revealed that lower cachexia rates, particularly with ...

View Full Profile. Learn about our Editorial Policies. Towards the final stages of diseases such as cancer and kidney disease, many patients develop cachexia, a devastating condition in which muscle ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284 ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side ...

Cachexia is a serious yet under-recognized consequence of many chronic diseases, including heart disease, kidney disease, chronic obstructive pulmonary disease and, most notably, cancer.

Cardiac cachexia is the weight loss and decrease in appetite that occurs during states of chronically low cardiac output and congestive heart failure. This gives a poor prognosis independent of ...

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

Vistagen (VTGN) announced results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia. The 'previously unreported ...